Physician profile
Aleksandr Martirosov
NPI 1700931185
$2,503.86
in general payments reported to CMS, 2019-2025
31 companies · $46.62 in 2025
The $46.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $660 · 2021: $512 · 2022: $322 · 2023: $192 · 2024: $150 · 2025: $46.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.24 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $281.60 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $268.64 | 2019-2023 | |
| Gilead Sciences, INC. | $221.75 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $187.64 | 2019-2023 | Livalo, Seglentis |
| Lilly USA, LLC | $170.11 | 2019-2024 | Zepbound, Mounjaro |
| Tactile Systems Technology INC | $123.18 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.18 | 2019-2021 | |
| Bausch Health US, LLC | $101.55 | 2019-2023 | Aplenzin |
| Allergan, INC. | $88.77 | 2019-2020 | |
| Novo Nordisk INC | $88.08 | 2019-2024 | Wegovy |
| Alkermes, INC. | $67.05 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $59.06 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $46.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.79 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $34.16 | 2024 | Grafix Pl |
| Antares Pharma, INC. | $29.98 | 2019 | |
| Currax Pharmaceuticals LLC | $28.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.81 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.59 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $25.78 | 2020-2023 | Kristalose |
| Abbott Laboratories | $22.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.62 | 2022 | |
| Merck Sharp & Dohme LLC | $14.87 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.86 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $14.56 | 2019 | |
| Horizon Therapeutics Plc | $14.52 | 2021 | |
| Tris Pharma INC | $13.66 | 2024 | Dyanavel Xr |
| Genentech USA, INC. | $13.50 | 2021 | |
| Bard Peripheral Vascular, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Martirosov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.